

Information Disclosure Statement by Applicant (use as many sheets as necessary)				Complete if Known	
Sheet	of			Application Number	10/632,711
				Filing Date	August 1, 2003
				First Named Inventor	Carson, Dennis A.
				Art Unit	1614
				Examiner Name	Not Yet Assigned
				Attorney Docket Number	023070-124010US

U.S. PATENT DOCUMENTS+					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number Kind Code <sup>2</sup> (if known)			
M6	AA	US-3,097,137	07-09-1963	Beer et al.	
	AB	US 3,205,220	09-07-1965	Svoboda et al.	
	AC	US-3,880,995	04-29-1975	Jones	
	AD	US-3,991,078	11-09-1976	Witkowski et al.	
	AE	US-4,136,175	01-23-1979	Rideout	
	AF	US-4,138,547	02-06-1979	Christensen et al.	
	AG	US-4,451,648	05-29-1984	Parsons et al.	
	AH	US-4,680,285	07-14-1987	Robins	
	AI	US-4,727,069	02-23-1988	Nelson et al.	
	AJ	US-4,753,935	08-28-1988	Nelson et al.	
	AK	US-4,788,637	11-22-1988	Allison et al.	
	AL	US-4,998,237	02-26-1991	Pettit et al.	
	AM	US-5,405,837	04-11-1995	Weber	
	AN	US-5,472,947	12-05-1995	Saida et al.	
	AO	US-5,492,897	02-20-1996	Krenitsky et al.	
	AP	US-5,561,122	10-01-1996	Kamp et al.	
	AQ	US-5,571,510	11-05-1996	Nobori et al.	
	AR	US-5,747,472	05-05-1998	Krenitsky et al.	
	AS	US-5,821,238	10-13-1998	Krenitsky et al.	
	AT	US-5,840,505	11-24-1998	Camera et al.	
	AU	US-5,942,393	08-24-1999	Nobori et al.	
	AV	US 6,162,810	12-19-2000	Carson et al.	
	AW	US-6,210,917	04-03-2000	Carson et al.	
	AX	US-6,214,571	04-10-2001	Camera et al.	
	AY	US-6,306,874	10-23-2001	Fraley et al.	
	AZ	US-6,395,763 B1	05-28-2002	Stamos et al.	
	BA	US-2002/0082678	06-27-2002	Sirhan et al.	

FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document
		Country Code <sup>3</sup>	Number <sup>4</sup>		
M6	BB	WO	98/40381	A1	09-17-1998
	BC	WO	99/55663	A1	11-04-1999
	BD	WO	00/10600	A2	03-02-2000
	BE	WO	00/26197	A1	05-11-2000
	BF	WO	00/33876	A1	06-15-2000
	BG	WO	00/35865	A2	06-22-2000
	BH	WO	00/40269	A2	07-13-2000

Examiner Signature	<i>Michael Stoffers</i>	Date Considered	10/21/08
--------------------	-------------------------	-----------------	----------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449B/PTO				<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>				Application Number	10/632,711
(use as many sheets as necessary)				Filing Date	August 1, 2003
				First Named Inventor	Carson, Dennis A.
				Art Unit	1614
				Examiner Name	Not Yet Assigned
Sheet	of			Attorney Docket Number	023070-124010US

<b>FOREIGN PATENT DOCUMENTS</b>								
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>2</sup>
		Country Code <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)				
MS	BI	WO	01/00622	A1	01-04-2001			<input type="checkbox"/>
	BJ	WO	01/87324	A1	11-22-2001			<input type="checkbox"/>
	BK	WO	04/12746	A3	02-12-2004			<input type="checkbox"/>

<b>NON PATENT LITERATURE DOCUMENTS</b>								
Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.					T <sup>2</sup>	
MS	BL	ALLISON, A.C. et al.; "Immunological Observations on Patients with Lesch-Nyhan Syndrome, and on the role of De-Novo Purine Transformation"; 1975, <u>The Lancet</u> , pp. 1179-1183.						
	BM	ALLISON, A.C. et al.; "The role of de novo purine synthesis in lymphocyte transformation"; 1977, <u>Ciba Found. Symp.</u> , Vol. 48, pp. 207-224.						
	BN	BEDDOWS, Clifford G. et al.; "Synthesis and reactions of 2-(5-amino-4-carbamoylimidazol-1-yl)-2-deoxy-D-glucose, an analog of a naturally occurring imidazole nucleoside"; 1975, <u>Chemical Abstracts Service</u> , 2 page abstract.						
	BO	CATAPANO, Carlo V. et al.; "GTP Depletion Induced by IMP Dehydrogenase Inhibitors Blocks RNA-Primed DNA Synthesis"; 1985, <u>Molecular Pharmacology</u> , Vol. 47, No. 5, pp. 948-955.						
	BP	CARLUCCI, Michael A. et al.; "Atrasentan, an Endothelin-Receptor Antagonist for Refractory Adenocarcinomas: Safety and Pharmacokinetics"; 2002, <u>Journal of Clinical Oncology</u> , Vol. 20, No. 8, pp. 2171-2180.						
	BQ	CHABNER, B.A. et al.; "Antineoplastic Agents"; 1996, <u>Goodman and Gilman's the Pharmacological Basis of Therapeutics</u> , Vol. 9, pp. 1243-1247.						
	BR	de BONO, Johann S. et al.; "The ErbB receptor family: a therapeutic target for cancer"; 2002, <u>Trends in Molecular Medicine</u> , Vol. 8, No. 4, pp. S19-S26.						
	BS	DHANASEKARAN, N. et al.; "G Protein-Coupled Receptor Systems Involved in Cell Growth and Oncogenesis"; 1995, <u>Endocrine Reviews</u> , Vol. 16, No. 3, pp. 259-270.						
	BT	DOWNS, Stephen M. et al.; "Induction of Mouse Oocyte Maturation in Vivo by Perturbants of Purine Metabolism"; 1987, <u>Biology of Reproduction</u> , Vol. 36, pp. 431-437.						
	BU	DRUKER, Brian J.; "ST1571 (Gleevec™) as a paradigm for cancer therapy"; 2002, <u>Trends in Molecular Medicine</u> , Vol. 8, No. 4, pp. S14-S18.						
	BV	ERLICHMAN, Charles; "Hormonal Therapies in Cancer"; 1997, <u>Principles and Practice in Oncology</u> , Vol. 5, pp. 395-405.						
	BW	FLANAGAN, Colleen A. et al.; "Advances in understanding gonadotrophin-releasing hormone receptor structure and ligand interactions"; 1997, <u>Reviews of Reproduction</u> , Vol. 2, pp. 113-120.						


Examiner Signature	<i>Michael Shaffer</i>	Date Considered	10/21/05
--------------------	------------------------	-----------------	----------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449B/PTO				Complete if Known	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>				Application Number	10/632,711
(use as many sheets as necessary)				Filing Date	August 1, 2003
				First Named Inventor	Carson, Dennis A.
				Art Unit	1614
				Examiner Name	Not Yet Assigned
Sheet		of		Attorney Docket Number	023070-124010US

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			T <sup>2</sup>
MB	BX	FOREMAN, Kimberly E.; "Kaposi's sarcoma: the role of HHV-8 and HIV-1 in pathogenesis"; 2001, <u>Expert Reviews</u> , pp. 1-17.			
	BY	FUKUI, Masaru et al.; "New Antitumor Imidazole Derivative, 5-Carbamoyl-1 H-Imidazol-4-yl Piperonylate, as an Inhibitor of Purine Synthesis and Its Activation by Adenine Phosphoribosyltransferase"; 1982, <u>Cancer Research</u> , Vol. 42, pp. 1098-1102.			
	BZ	GANDHI, Varsha.; "Novel Inhibitors of DNA Replication"; 1999, <u>Hematology</u> , pp. 483-469.			
	CA	GILCHRIST, Annette et al.; "Antagonists of the Receptor-G Protein Interface Block G-Coupled Signal Transduction"; 1998, <u>The Journal of Biological Chemistry</u> , Vol. 273, No. 24, pp. 14912-14919.			
	CB	GLASSOCK, Richard J.; "The treatment of IgA nephropathy: status at the end of the millennium"; 1999, <u>J. Nephrol</u> , Vol. 12, pp. 288-298.			
	CC	GREGORY, R.K. et al.; "Vinorelbine - a clinical review"; 2000, <u>British Journal of Cancer</u> , Vol. 82, No. 12, pp. 1907-1913.			
	CD	GUPTA, R.S. et al.; "Cross resistance pattern towards anticancer drugs of a human carcinoma multidrug-resistant cell line"; 1988, <u>Br. J. Cancer</u> , Vol. 58, pp. 441-447.			
	CE	HEALY, Dennis P.; "[28] Genetic Analysis of G Protein-Coupled Receptor Genes, 2002, <u>Methods in Enzymology</u> , Vol. 353, pp. 448-459.			
	CF	HOESSEL, Ralph et al.; "Indirubin, the active constituent of a Chinese antileukaemia medicine, Inhibits cyclin-dependent kinases"; 1999, <u>Nature Cell Biology</u> , Vol. 1, pp. 60-67.			
	CG	HUA, Xuequn Helen et al.; "Biochemical Genetic Analysis of Indanocine Resistance In Human Leukemia"; 2001, <u>Cancer Research</u> , Vol. 61, pp. 7248-7254.			
	CH	INSEL, P.; "Analgesic-Antipyretic and Antiinflammatory Agents and Drugs Employed in the Treatment of Gout"; 1996, <u>Goodman and Gilman's the Pharmacological Basis of Therapeutics</u> , Vol. 9, pp. 647-649.			
	CI	ISHIKAWA, Hiroaki; "Mizoribine and Mycophenolate Mofetil"; 1999, <u>Current Medicinal Chemistry</u> , Vol. 6, pp. 575-597.			
	CJ	JEMAL, Ahmedin et al.; "Cancer Statistics 2002"; 2002, <u>CA Cancer J. Clin.</u> , Vol. 52, pp. 23-47.			
	CK	KARAGIRL, Nobuya et al.; "Synthesis of Pyrazofurin and its Analogues"; 1984, <u>J. Chem. Soc. Perkin Trans. 1</u> , pp. 553-580.			
	CL	KISLIUK, Roy L.; "Synergistic Interactions among antifolates"; 2000, <u>Pharmacology &amp; Therapeutics</u> , Vol. 85, pp. 183-190.			
	CM	KISOR, David F. et al.; "Pharmacokinetics of Nelarabine and 9-Beta-d-Arabinofuranosyl Guanine in Pediatric and Adult Patients During a Phase I Study of Nelarabine for the Treatment of Refractory Hematologic Malignancies"; 2000, <u>Journal of Clinical Oncology</u> , Vol. 18, No. 5, pp. 995-1003.			

Examiner Signature		Date Considered	10/21/05
--------------------	--	-----------------	----------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449B/PTO				<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(use as many sheets as necessary)</i>					
Sheet		of		Application Number	10/632,711
				Filing Date	August 1, 2003
				First Named Inventor	Carson, Dennis A.
				Art Unit	1614
				Examiner Name	Not Yet Assigned
				Attorney Docket Number	023070-124010US

<b>NON PATENT LITERATURE DOCUMENTS</b>					
Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			T <sup>2</sup>
UMb	CN	LEONI, Lorenzo M. et al.; "Indanocine, a Microtubule-Binding Indanone and a Selective Inducer of Apoptosis in Multidrug-Resistant Cancer Cells"; 2000, <u>Journal of the National Cancer Institute</u> , Vol. 92, No. 3, pp. 217-224.			
	CO	MACKENZIE, Grahame et al.; "Purines, pyrimidines, and imidazoles. Part 48. Some acyclic D-arabinose imidazole and purine nucleosides"; 1977, <u>Chemical Abstracts Service</u> , 2 page abstract.			
	CP	MACKENZIE, Grahame et al.; "Synthesis of a novel acyclic D-arabinose nucleoside"; 1975, <u>Chemical Abstracts Service</u> , 2 page abstract.			
	CQ	MAJUMDAR, Alokes et al.; "IL-3 and Ribavirin Induce Differentiation and Growth Suppression During Long-Term Treatment of a Megakaryocytic Leukemia Cell Line"; 1995, <u>Journal of Cellular Physiology</u> , Vol. 165, pp. 530-537.			
	CR	MIZUNO, Kimio, et al.; "Studies on Breddinin. I: Isolation, Characterization and Biological Properties"; 1974, <u>The Journal of Antibiotics</u> , Vol. 27, No. 10, pp. 775-782.			
	CS	MORRIS, Randall E.; "Mechanisms of action of new immunosuppressive drugs"; 1996, <u>Kidney International</u> , Vol. 49, Supple. 53, pp. S28-S38.			
	CT	NAGY, Attila et al.; "Synthesis and biological evaluation of cytotoxic analogs of somatostatin containing doxorubicin or its intensely potent derivative, 2-pyrrolinodoxorubicin"; 1998, <u>PNAS</u> , Vol. 95, pp. 1794-1799.			
	CU	OLAH, Edith et al.; "Induction of erythroid differentiation and modulation of gene expression by tiazofurin in K-562 leukemia cells"; 1988, <u>PNAS</u> , Vol. 85, pp. 6533-6537.			
	CV	OLAH, Edith et al.; "Molecular Mechanisms in the Antiproliferative Action of Taxol and Iazofurin"; 1996, <u>Anticancer Research</u> , Vol. 16, pp. 2469-2478.			
	CW	PRAJDA, Noemi et al.; "Sequential Impact of Tiazofurin and Ribavirin on the Enzymic Program of the Bone Marrow"; 1993, <u>Cancer Research</u> , Vol. 53, pp. 5982-5986.			
	CX	PRENZEL, Norbert et al.; "EGF receptor transactivation by G-protein-coupled receptors requires metalloproteinase cleavage of proHB-EGF"; 1999, <u>Nature</u> , Vol. 402, pp. 884-888.			
	CY	Roy, K.K. et al.; "Early Development of Cyclin Dependent Kinase Modulators"; 2001, <u>Current Pharmaceutical Design</u> , Vol. 7, pp. 1669-1687.			
	CZ	SEASHOLTZ, Tammy M. et al.; "Rho as a Mediator of G Protein-Coupled Receptor Signaling"; 1999, <u>The American Society for Pharmacology and Experimental Therapeutics</u> , Vol. 55, pp. 949-956.			
	DA	SEIDENFELD, Jerome et al.; "Androgenic Regulation of 5'-Deoxy-5'-Methylthioadenosine Concentrations and Methylthioadenosine Phosphorylase Activity in Relation to Polyamine Metabolism of Rat Prostate"; 1980, <u>Biochemical and Biophysical Research Communications</u> , Vol. 95, No. 4, pp. 1861-1868.			
	DB	SEUWEN, Klaus et al.; "G Protein-Controlled Signal Transduction Pathways and the Regulation of Cell Proliferation"; 1992, <u>Advances in Cancer Research</u> , Vol. 58, pp. 75-94.			
	DC	SHAW, Leslie M. et al.; "Mycophenolate Mofetil: A Report of the Consensus Panel"; 1995, <u>Therapeutic Drug Monitoring</u> , Vol. 17, pp. 690-699.			

Examiner Signature	<i>Michael Jaffee</i>	Date Considered	10/2, 101
--------------------	-----------------------	-----------------	-----------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449B/PTO				Complete if Known	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>				Application Number	10/632,711
(use as many sheets as necessary)				Filing Date	August 1, 2003
				First Named Inventor	Carson, Dennis A.
				Art Unit	1614
				Examiner Name	Not Yet Assigned
Sheet		of		Attorney Docket Number	023070-124010US

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			T <sup>2</sup>
MB	DD	SHAWYER, Laura K. et al.; "Smart Drugs: Tyrosine kinase inhibitors in cancer therapy"; 2002, <u>Cancer Cell</u> , Vol. 1, pp. 117-132.			
	DE	SLICHENMYER, William J. et al.; "Anticancer Therapy Targeting the ErbB Family of Receptor Tyrosine Kinases"; 2001, <u>Seminars in Oncology</u> , Vol. 28, No. 5, Suppl. 16, pp. 67-79.			
	DF	SODHI, Akrit et al.; "The Kaposi's Sarcoma-associated Herpes Virus G Protein-coupled Receptor Up-Regulates Vascular Endothelial Growth Factor Expression and Secretion through Mitogen-activated Protein Kinase and p38 Pathways Acting on Hypoxia-inducible Factor 1 $\alpha$ "; 2000, <u>Cancer Research</u> , Vol. 60, pp. 4873-4880.			
	DG	SOLLINGER, H.W. et al.; "Mycophenolate Mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients"; 1995, <u>Transplantation</u> , Vol. 60, No. 3, pp. 225-232.			
	DH	STRANGE, Philip G.; "Agonist binding to G-protein coupled receptors"; 2000, <u>British Journal of Pharmacology</u> , Vol. 129, pp. 820-821.			
	DI	THOMSON, A.W. et al.; "Effects of combined administration of FK 508 and the purine biosynthesis inhibitors mizoribine or mycophenolic acid on lymphocyte DNA synthesis and T cell activation molecule expression in human mixed lymphocyte cultures"; 1993, <u>Transplant Immunology</u> , Vol. 1, pp. 146-150.			
	DJ	TRICOT, Guido et al.; "Tiazofurin: Biological Effects and Clinical Uses"; 1990, <u>International Journal of Cell Cloning</u> , Vol. 8, pp. 161-170.			
	DK	VALLEE, Sebastien et al.; "Ribavirin-induced resistance to heat shock, inhibition of the Ras-Raf-1 pathway and arrest in G <sub>1</sub> "; 2000, <u>European Journal of Pharmacology</u> , Vol. 4, pp. 49-62.			
	DL	WEBER, George; "Advances in Enzyme Regulation"; 1989, <u>Proceedings of the International Conference on Critical Issues in Chemotherapy</u> , Vol. 29, pp. 75-95.			
	DM	WEBER, George; "Purine and Pyrimidine Metabolism in Man VII"; 1991, <u>Advances in Experimental Medicine and Biology</u> , Vol. 309B, pp. 287-292.			
	DN	WEBER, George et al.; "Tiazofurin Down-Regulates Expression of c-Ki-ras Oncogene in a Leukemic Patient"; 1991, <u>Cancer Communications</u> , Vol. 3, No. 3, pp. 61-68.			
	DO	WOOLAM, Gerald L.; "Cancer Statistics 2000: A Benchmark for the New Century"; 2000, <u>CA Cancer J. Clin.</u> , Vol. 50, No. 7, pp. 33.			
	DP	YALOWITZ, Joel A. et al.; "Molecular Targets of Guanine Nucleotides in Differentiation, Proliferation and Apoptosis"; 2000, <u>Anticancer Research</u> , Vol. 20, pp. 2329-2338.			
	DQ	ZOU, Ruiming et al.; "Synthetic Approaches to the Guanosine and Xanthosine Analogues 5-Amino-3- $\beta$ -D-ribofuranosylpyrazolo[3,4-3][1,3]oxazin-7-one and 3- $\beta$ -D-Ribofuranosylpyrazolo[3,4-e][1,3]oxazine-5,7-dione and Studies of Their Antitumor Potential"; 1991, <u>J. Med. Chem.</u> , Vol. 34, pp. 1951-1959.			

Examiner Signature	<i>Michael Shaffie</i>	Date Considered	10/21/05
--------------------	------------------------	-----------------	----------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.